Monopar Therapeutics (MNPR) Return on equity 2016–2025
Monopar Therapeutics (MNPR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-10.0%FY2025 · since FY2016: -41.9% → -10.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -10.0% | +18.4 pp |
| FY2024 | -28.3% | — |
| FY2019 | -33.5% | +13.2 pp |
| FY2018 | -46.7% | +125.4 pp |
| FY2017 | -172.1% | -130.2 pp |
| FY2016 | -41.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice